Source: Kompas.com | Editor: Khomarul Hidayat
KONTAN.CO.ID – JAKARTA. Eijkman Amin Soebandrio Director of the Institute for Molecular Biology (LBM) is targeting the Red and White Vaccine, which they are currently developing, to enter the clinical trial stage at the end of this year.
With that target, an emergency use authorization (UEA) from the Food and Drug Administration (BPOM) can be obtained in mid-2022.
“It is hoped that clinical trials can start at the end of this year, in the fourth quarter of this year and be completed in approximately eight months, so that the EUA is expected to be obtained by the middle of next year,” Amin said in a discussion on Polemic MNC Trijaya FM, Saturday (17/4).
He said LBM Eijkman was trying to speed up the clinical trial process. However, Amin emphasized that no stage would be missed.
“This means that all steps must be followed, even though some are condensed or carried out in parallel, but all must be done,” he said.
Amin explained that the Covid-19 vaccine developed by LBM Eijkman uses a recombinant protein platform. The vaccine will then be injected into the recipient’s body twice.
“What is being developed by our Eijkman Institute uses recombinant protein from S and N proteins,” he said.
Regarding the Red and White Vaccine, Head of BPOM Penny Lukito previously said that vaccine development with various platforms enriched the experience and increased the ability of Indonesian researchers to master vaccine technology.
The clinical trial of the Red and White vaccine developed by Universitas Airlangga with an inactivated virus platform is targeted to be completed in the fourth quarter of 2021 and mass production in early 2022.
Meanwhile, the clinical trial of a recombinant protein vaccine developed by the Eijkman Institute for Molecular Biology is targeted for mass production in the second semester of 2022.
“At the same time, production facilities are being prepared at Bio Farma,” said Penny.
Director of Bio Farma Honesti Basyir said that his party is preparing a production facility for the Red and White vaccine. The production building was activated to increase the vaccine production capacity.
“If it is not enough, we will cooperate with the private pharmaceutical industry,” he said.
Also Read: Eijkman Institute: There are inconsistencies in research protocols related to domestic vaccines
Author: Tsarina Maharani
Editor: Bayu Galih
This article has been published on Kompas.com with the title “LBM Eijkman Targets Red and White Vaccine to Get BPOM Permit in mid-2022“.
DONATION, Get Free Vouchers!
As an expression of gratitude for your attention, there are free vouchers worth donations that can be used shopping at HAPPY STORE.
– –
<!–
Source: Kompas.com
Editor: Khomarul Hidayat
– <!–
